Olema Pharmaceuticals, Inc.
General ticker "OLMA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.7B (TTM average)
Olema Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -24.3%.
Estimated limits based on current volatility of 3.0%: low 6.57$, high 6.98$
Factors to consider:
- Total employees count: 131 (+36.5%) as of 2025
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: No approved products, Need additional capital, Clinical trial delays, Regulatory and compliance, Market competition
- Current price 38.8% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [10.75$, 28.73$]
- 2026-12-31 to 2027-12-31 estimated range: [7.08$, 19.61$]
Financial Metrics affecting the OLMA estimates:
- Negative: with PPE of -14.2 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: Shareholder equity ratio, % of 89.71 > 81.92
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
- Negative: Investing cash flow per share per price, % of -6.77 <= -4.49
Short-term OLMA quotes
Long-term OLMA plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $104.96MM | $142.26MM | $178.70MM |
| Operating Income | $-104.96MM | $-142.26MM | $-178.70MM |
| Non-Operating Income | $8.31MM | $12.78MM | $16.25MM |
| R&D Expense | $86.14MM | $124.52MM | $157.70MM |
| Income(Loss) | $-96.66MM | $-129.47MM | $-162.45MM |
| Net Income(Loss)* | $-96.66MM | $-129.47MM | $-162.45MM |
| Stockholders Equity | $253.90MM | $408.96MM | $478.56MM |
| Assets | $276.94MM | $450.98MM | $533.43MM |
| Operating Cash Flow | $-83.73MM | $-104.35MM | $-146.72MM |
| Capital expenditure | $0.00MM | $0.16MM | $0.00MM |
| Investing Cash Flow | $-4.85MM | $-93.53MM | $-155.76MM |
| Financing Cash Flow | $133.41MM | $268.82MM | $211.30MM |
| Earnings Per Share** | $-2.14 | $-2.20 | $-1.87 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.